Antibacterial methods and compositions

• US 20040224981A1
• Filed: 05/03/2004
• Published: 11/11/2004
• Est. Priority Date: 05/01/2003
• Status: Abandoned Application

• Current Assignee: Replidyne, Inc. (Boston Scientific Corporation)
• Original Assignee: Replidyne, Inc. (Boston Scientific Corporation)
• Inventors: Janjic, Nebojsa, Guiles, Joseph, Tarasow, Theodore M., Critchley, Ian A.
• Application Number:
  US10/837,881
• Publication Number:
  US 20040224981A1
• Time in Patent Office: Days
• US Class Current: 514/312
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed is a pharmaceutical composition comprising an aminoacyl tRNA synthetase inhibitor and another antibacterial agent, including another aminoacyl tRNA synthetase inhibitor.

Claims

1. A composition comprising an aminoacyl tRNA synthetase inhibitor or a pharmaceutically acceptable salt thereof, and an additional antibacterial agent.

2. A composition comprising a combination of two or more aminoacyl tRNA synthetase inhibitors, or the pharmaceutically acceptable salts thereof.

17. A method of treating a bacterial infection, comprising administering the pharmaceutical composition of claim 2 to a host having a bacterial infection.

18. The method of claim 17, wherein the bacterial infection is an infection of a an enterococcus.

19. The method of claim 18, wherein the enterococcus is selected from the group consisting of E. faecalis and E. faecium.

20. The method of claim 17, wherein the enterococcus is a vancomycin-resistant strain.

21. The method of claim 17, wherein the bacterial infection is an infection of a bacterium selected from the group consisting of S. aureus, S. pyogenes, S. epidermidis, and S. hemolyticus.

22. The method of claim 21, wherein the S. aureus is selected from the group consisting of vancomycin-intermediate S. aureus, low-level mupirocin-reistant S. aureus and high-level mupirocin-reistant S. aureus.

23. The method of claim 17, wherein the bacterial infection is an infection of a bacterium selected from the group consisting of S. aureus, S. pyogenes, S. epidermidis, and S. hemolyticus.

24. The method of claim 21, wherein the S. aureus is selected from the group consisting of vancomycin-intermediate S. aureus, low-level mupirocin-reistant S. aureus and high-level mupirocin-reistant S. aureus.

3. A composition comprising a methionyl tRNA synthetase inhibitor or a pharmaceutically acceptable salt thereof and an antibacterial agent.

4. The composition of claim 3 wherein the antibacterial agent is an aminoacyl tRNA synthetase inhibitor or a pharmaceutically acceptable salt thereof.

5. The composition of claim 4 wherein the aminoacyl tRNA synthetase inhibitor is an isoleucyl tRNA synthetase inhibitor.

6. The composition of claim 5 wherein the isoleucyl tRNA synthetase inhibitor is mupirocin or a pharmaceutically acceptable salt or ester thereof.

7. The composition of claim 3 wherein the methionyl tRNA synthetase inhibitor is selected from the group consisting of:

8. The composition of claim 7 wherein the methionyl tRNA synthetase inhibitor is

9. A pharmaceutical composition for topical application to humans or domestic mammals comprising mupirocin or a pharmaceutically acceptable salt or ester thereof, and at least one additional tRNA synthetase inhibitor or a pharmaceutically acceptable salt thereof.

10. A composition comprising a salt of a methionyl tRNA synthetase inhibitor wherein the salt is selected from the group consisting of the Mupirocinate salt and the Fusidate salt.

11. The composition claim 10, wherein the methionyl tRNA synthetase inhibitor is selected from the group consisting of:

12. The composition of claim 11 comprising N-(4,5-Dibromo-3-methylthiophen-2-ylmethyl)-N′

-(1H-quinolin-4-one)propane-1,3-diamine Mupirocinate.

13. The composition of claim 11 composition comprising N-(4-bromo-5-(1-fluorovinyl)-3-methylthiophen-2-ylmethyl)-N′

-(1H-quinolin-4-one)propane-1,3-diamine Mupirocinate.

14. The composition of claim 11 composition comprising N-(3-Chloro-5-methoxy-1H-indol-2-ylmethyl)-N′

-(1H-imidazo[4,5-b]pyridin-2-yl)-propane-1,3-diamine Mupirocinate.

15. The composition of claim 11 comprising N-(1H-imidazo[4,5-b]pyridin-2-yl)-N′

-(3,4,6-trichloro-1H-indol-2-ylmethyl)-propane-1,3-diamine Mupirocinate.

16. The composition of claim 11 comprising N-(1H-imidazo[4,5-b]pyridin-2-yl)-N′

-(3,4,6-trichloro-1H-indol-2-ylmethyl)-propane-1,3-diamine Fusidinate.